Coherus Bio (CHRS) Stock Price, Quote & News

Company Profile

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigat...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 649 3530

Website: www.coherus.com

Address:

333 Twin Dolphin Drive, Suite 600, Redwood City, United States

Sarandon Jan. 14 at 4:46 PM

$CHRS 💎Let's not forget that... "In this exploratory post-hoc analysis, patients receiving LOQTORZI plus gemcitabine and cisplatin achieved a median OS of 64.8 months, nearly double that of chemotherapy alone (33.7 months), representing a 31-month improvement and an observed 38% reduction in risk of death (HR 0.62; 95% CI, 0.45–0.85). These results, presented at ESMO Asia 2025, signal a step change in cancer patient survival, reinforcing LOQTORZI’s role in transforming outcomes for people living with RM-NPC."

0 · Reply

Sarandon Jan. 14 at 4:38 PM

$CHRS Compared to other companies in the sector, Coherus is very cheap; it wouldn't be surprising if another company bought it. 💪💎

0 · Reply

Sarandon Jan. 14 at 4:19 PM

$CHRS 💎🚀🔥

0 · Reply

neofeudal Jan. 14 at 4:16 PM

$CHRS PT of $6 remains. Company actions support it more than ever.

0 · Reply

neofeudal Jan. 14 at 4:00 PM

$CHRS $1.74 near-term. VERY near.

0 · Reply

Jack_Nicholson_Truth Jan. 14 at 3:57 PM

$CHRS mm playing their usual games. Daily range is 10-15% here.

0 · Reply

Jack_Nicholson_Truth Jan. 14 at 2:46 PM

$CHRS we got us a big seller or algo this am Shorts on the attack but will they finally have to covef

1 · Reply

Jack_Nicholson_Truth Jan. 14 at 2:31 PM

$CHRS no premarket volume. Tariff news will dominate am but after jpm, big tell will be do we go up from here or do we go back to $1.4? CCR8 could have MULTIPLE competitor readouts in 2026.Prior shiniogi and Lm108 didn't impact chrs stock price at all (Lm108 has Btd in China for gastric, shiniogi says ccr8 is future for crc)

0 · Reply

BigDaddyCapital Jan. 14 at 1:17 PM

$CHRS Tagmokitug is pretty strong, Casdozo is up there too. Pipeline story, Denny knows this & they know what they have. Loqtorzi sales does not matter here. They likely have deals done for assets or company sale contingent with data releases in 2026. They also have a solid cash reserve, TSA stuff translated into cash for CHRS.

1 · Reply

Jack_Nicholson_Truth Jan. 14 at 1:05 PM

$CHRS remember that coherus has a stronger, more direct ccr8 than shiniogi. AND THEY ALREADY ANNOUNCED THEY WILL GET THEIR CCR8 APPROVED AND FOR SALE in Japan by 2030. This is AFTER A P1 SOLID TUMOR TRIAL. My pt is that already derisks chs114 as why would shiniogi put out a NATIONAL PR about making their ccr8 the foundation for their io cancer pipeline.

0 · Reply

Coherus Oncology, Inc. (CHRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 6, 2026, 9:30 AM EST - 8 days ago

Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 9:30 AM EST - 9 days ago

Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)

Dec 23, 2025, 11:06 AM EST - 22 days ago

Coherus Oncology: A Two-Pronged March With Mid-2026 Implications

Dec 8, 2025, 8:30 AM EST - 5 weeks ago

Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma

Nov 10, 2025, 5:01 PM EST - 2 months ago

Coherus Oncology, Inc. (CHRS) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 7, 2025, 5:56 PM EST - 2 months ago

Coherus Oncology, Inc. (CHRS) Q3 2025 Earnings Call Transcript

Nov 7, 2025, 9:00 AM EST - 2 months ago

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

Nov 6, 2025, 4:14 PM EST - 2 months ago

Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 6, 2025, 1:54 PM EST - 2 months ago

Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

Oct 30, 2025, 8:30 AM EDT - 2 months ago

Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 23, 2025, 8:30 AM EDT - 2 months ago

Coherus Oncology to Participate in Upcoming Investor Conferences

Oct 10, 2025, 4:32 AM EDT - 3 months ago

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals

ALDX ALEC BDTX

Oct 3, 2025, 9:05 AM EDT - 3 months ago

Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 1, 2025, 5:02 PM EDT - 3 months ago

Coherus Oncology, Inc. (CHRS) Presents at UBS Virtual Oncology Day Transcript

Oct 1, 2025, 10:43 AM EDT - 3 months ago

Coherus Oncology: Five Readouts Or More Possible In 2026

Aug 25, 2025, 4:55 PM EDT - 5 months ago

Coherus Oncology: On The Shaping Up

Aug 9, 2025, 11:35 AM EDT - 5 months ago

Coherus Oncology, Inc. (CHRS) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:41 PM EDT - 5 months ago

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 4:45 PM EDT - 5 months ago

Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

May 12, 2025, 10:46 PM EDT - 8 months ago

Coherus BioSciences, Inc. (CHRS) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:15 PM EDT - 8 months ago

Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 4:01 PM EDT - 9 months ago

Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

May 1, 2025, 5:04 PM EDT - 9 months ago

Coherus to Participate in Upcoming Investor Conferences

Apr 28, 2025, 10:10 AM EDT - 9 months ago

Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025

Apr 17, 2025, 5:53 AM EDT - 9 months ago

Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs

Apr 14, 2025, 8:00 AM EDT - 9 months ago

Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise

Mar 25, 2025, 4:30 PM EDT - 10 months ago

Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 10, 2025, 8:52 PM EDT - 11 months ago

Coherus BioSciences, Inc. (CHRS) Q4 2024 Earnings Call Transcript

Mar 10, 2025, 4:12 PM EDT - 11 months ago

Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update

Mar 3, 2025, 8:30 AM EST - 11 months ago

Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025

Feb 24, 2025, 9:08 AM EST - 11 months ago

Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference

Dec 18, 2024, 8:30 AM EST - 1 year ago

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

Dec 16, 2024, 6:08 PM EST - 1 year ago

Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development

Dec 3, 2024, 9:34 AM EST - 1 year ago

Why Is Coherus BioSciences Stock Trading Higher On Tuesday?

Nov 27, 2024, 4:01 PM EST - 1 year ago

Coherus Management to Participate in the 2024 Citi Global Healthcare Conference

Nov 6, 2024, 11:09 PM EST - 1 year ago

Coherus BioSciences, Inc. (CHRS) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:01 PM EST - 1 year ago

Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 30, 2024, 4:20 PM EDT - 1 year ago

Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024

Aug 13, 2024, 10:01 AM EDT - 1 year ago

Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects

Aug 9, 2024, 6:08 PM EDT - 1 year ago

Coherus BioSciences, Inc. (CHRS) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 9:00 AM EDT - 1 year ago

Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024

Jun 27, 2024, 8:26 AM EDT - 1 year ago

Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction

May 31, 2024, 12:04 PM EDT - 1 year ago

Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway

May 30, 2024, 9:00 AM EDT - 1 year ago

Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference

May 23, 2024, 5:51 PM EDT - 1 year ago

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 23, 2024, 9:00 AM EDT - 1 year ago

Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA

May 10, 2024, 12:07 AM EDT - 1 year ago

Coherus BioSciences, Inc. (CHRS) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:01 PM EDT - 1 year ago

Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 7:30 AM EDT - 1 year ago

Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan

Sarandon Jan. 14 at 4:46 PM

0 · Reply

Sarandon Jan. 14 at 4:38 PM

$CHRS Compared to other companies in the sector, Coherus is very cheap; it wouldn't be surprising if another company bought it. 💪💎

0 · Reply

Sarandon Jan. 14 at 4:19 PM

$CHRS 💎🚀🔥

0 · Reply

neofeudal Jan. 14 at 4:16 PM

$CHRS PT of $6 remains. Company actions support it more than ever.

0 · Reply

neofeudal Jan. 14 at 4:00 PM

$CHRS $1.74 near-term. VERY near.

0 · Reply

Jack_Nicholson_Truth Jan. 14 at 3:57 PM

$CHRS mm playing their usual games. Daily range is 10-15% here.

0 · Reply

Jack_Nicholson_Truth Jan. 14 at 2:46 PM

$CHRS we got us a big seller or algo this am Shorts on the attack but will they finally have to covef

1 · Reply

Jack_Nicholson_Truth Jan. 14 at 2:31 PM

0 · Reply

BigDaddyCapital Jan. 14 at 1:17 PM

1 · Reply

Jack_Nicholson_Truth Jan. 14 at 1:05 PM

0 · Reply

biid Jan. 14 at 3:47 AM

$CHRS Denny, regarding approach to community (vs. academic) setting: "In academia, the physicians are very proficient regarding NCCN guidelines and standard of care and evolving practices. [NPC] is a rare disease...only 2000 patients...so that means that the community physicians see...a patient every one or two years...the rest of the time, they're seeing breast cancer, lung cancer, and...these more common cancer patients. So it is more difficult to have the opportunity to educate the community physicians so we have to reach out to them. So what we've done is we've put in place a sophisticated system of alerts. Last year we were able to detect about 30 to 35 percent of the alerts in the patients that are diagnosed by receiving data on the diagnosis codes. This year, we just completed a project in which we grew up to 65 or 70 percent. We've also enhanced our team with additional headcount to reach each of these physicians as they get a patient."

0 · Reply

Jack_Nicholson_Truth Jan. 14 at 2:03 AM

$CHRS very interesting small option trade this am. 9:53am Jan 16 $1 strike someone sold 800 calls for 0.60 when chrs was $1.62. That's how I know it was a sell as to buy that call would have cost 0.90 or $1. It's interesting because you rarely see 50k options trade for any reason here. MM are planning something.

1 · Reply

biid Jan. 14 at 1:54 AM

$CHRS Denny announced the (rough) UDENYCA milestone payment timeframes: Q3 2026: $37.5M Q1 2027: $37.5M Said those milestones are "not included in the [cash projections] but...those market opportunities are moving forward very well...in particular in the hands of INTAS Accord, UDENYCA has achieved over 35% market share most recently." Would be great to get two quarters' worth of cash burn back, especially as LOQ sales increases chip away at the cash burn rate.

1 · Reply

Grandgustav Jan. 14 at 12:18 AM

$CHRS burn rate slowed last quarter, suggesting we have some time before cash becomes a bigger issue. the udenyca earnouts and just one additional deal or approval would solidify our position. long term, the sky is the limit. if we get these cancer drugs on the market, holy shit, for real

1 · Reply

AccuRoger Jan. 13 at 11:38 PM

$CHRS One of the comments on the call today referenced the difficulty of getting a drug into a solid tumor to include the follow-on effect of the right kind of Tcells. I own shares in Trisalus that has a pressure-enabled device to overcome this barrier. They could benefit from access to a proprietary PD-1 (Toripalimab). There is more: The TLSI CEO was previously on the Coherus BOD. AND…There isn't a direct "overlap" in board members between Coherus BioSciences and TriSalus Life Sciences in the sense of shared directors currently, but there was historical overlap with Mats Larsson, who served as Lead Independent Director for Coherus and later joined the board of TriSalus. CHRS has an elderly CEO who is acting like he is already retired (i.e, selling bio similar assets). I am thinking merger of equals with exchange of shares only. Both companies have modest Revenue. CHRS has Cash but TLSI with small Debt is headed toward cash flow positive in 2026. Just thinking out loud.

1 · Reply

Jack_Nicholson_Truth Jan. 13 at 11:02 PM

$CHRS we have been trapped under $1.70 since the Yusimry divestiture started. Any pop above has been shorted down WITHIN a day everytime. True story that June 2024 chrs bonds went 50% down around the same time which triggered the massive equity shorting campaign. Denny PAID THEM ALL BACK and those bonds made money and they made a fortune on the short. NOW the divest is over, chrs is fully an ONCO Co and back to this same price. So rerate might happen just for that?

0 · Reply

TeamDSM Jan. 13 at 10:48 PM

$CHRS

0 · Reply

Microcap777 Jan. 13 at 9:07 PM

$CHRS Nice recovery. I have the same concerns as everyone, but I keep coming back to my gut: With all the potential this HAS to be worth at least $400M and more like $600M even with the concerns everyone has pointed out. Still here, still loaded up, still waiting.

2 · Reply

Jack_Nicholson_Truth Jan. 13 at 8:51 PM

$CHRS he said the samething he always said except he said chs114 in one year. They can't dilute much here without any chance of surviving past 2026 so partner or die imho. But the chart looks so promising to breakout soon. How many retests of $1.70 SINCE JUNE 2024. You can't borrow your market cap or atm your market cap without debt spiral. Sgmo is a great example. Shorts will kill it for you.

1 · Reply

scandinavianleaf Jan. 13 at 8:26 PM

$CHRS How did you interpret the sentiment that Lanfear (or whoever who were talking) were talking about partnership/deals? Was it more in the ballpark of "we have an intention to find partnerships", or "we are actively discussing/pursuing deals"? *Any other thing that stood out?

1 · Reply

vsingh120582 Jan. 13 at 8:14 PM

$CHRS Is it fair to say they don't have data that is not exciting enough for large pharma?...otherwise why would they are betting on supply collaboration if the product is really showing exceptional sign in ongoing trials?

1 · Reply

JohnTrack Jan. 13 at 8:10 PM

$CHRS watching the flow here!

0 · Reply

Market Cap	90.31M
Revenue (ttm)	266.96M
Net Income (ttm)	28.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	10.68%
Debt to Equity Ratio	-0.20

Volume	1,822,400
Avg Vol	1,708,078
Day's Range	N/A - N/A
Shares Out	115.93M
Stochastic %K	30%
Beta	1.01
Analysts	Strong Sell
Price Target	$5.26